GlassScriptPhysician profile
Amberly Taite Eversole
NPI 1508620733
$4,467.91
in general payments reported to CMS, 2019-2025
26 companies · $1,744 in 2025
The $1,744 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,723 · 2025: $1,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,328 · Travel and Lodging: $1,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,328.03 |
| Travel and Lodging | $1,139.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $1,604.49 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $506.92 | 2024-2025 | Repatha, Tepezza, Tavneos |
| Novo Nordisk INC | $321.89 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $301.15 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $220.28 | 2025 | Freestyle Libre, Freestyle Libre 3 |
| Recordati_rare_diseases_inc. | $208.55 | 2024-2025 | Isturisa, Signifor Lar |
| Bayer Healthcare Pharmaceuticals INC. | $175.73 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $171.99 | 2025 | |
| Lilly USA, LLC | $154.17 | 2024-2025 | Mounjaro, Zepbound, Trulicity |
| Radius Health, INC. | $154.12 | 2024-2025 | Tymlos |
| Insulet Corporation | $94.52 | 2025 | Omnipod |
| Antares Pharma, INC. | $88.13 | 2024-2025 | Xyosted |
| Medtronic, INC. | $75.23 | 2025 | Minimed 780g |
| Chiesi USA, INC. | $73.39 | 2024-2025 | Mycapssa, Myalept |
| Averitas Pharma INC. | $40.14 | 2024-2025 | Qutenza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $37.31 | 2025 | |
| Pfizer INC. | $35.01 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.96 | 2025 | Jardiance |
| Neurocrine Biosciences, INC. | $27.76 | 2025 | |
| Kyowa Kirin, INC. | $24.31 | 2025 | |
| Corcept Therapeutics | $24.15 | 2024 | Korlym |
| Alvogen INC | $22.73 | 2024 | Teriparatide |
| Otsuka America Pharmaceutical, INC. | $22.27 | 2024 | Rexulti |
| Regeneron Healthcare Solutions, INC. | $20.99 | 2025 | Evkeeza |
| Abbvie INC. | $15.67 | 2025 | |
| Xeris Pharmaceuticals, INC. | $14.05 | 2025 | Recorlev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amberly Eversole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.